Sites of initial bleeding episodes, mode of delivery and age of diagnosis in babies with haemophilia diagnosed before the age of 2 years: a report from The Centers for Disease Control and Prevention’s (CDC) Universal Data Collection (UDC) project
Lack of detailed natural history and outcomes data for neonates and toddlers with haemophilia hampers the provision of optimal management of the disorder. We report an analysis of prospective data collected from 580 neonates and toddlers aged 0–2 years with haemophilia enrolled in the Universal Data Collection (UDC) surveillance project of the Centers for Disease Control and Prevention (CDC). This study focuses on a cohort of babies with haemophilia whose diagnosis was established before the age of two. The mode of delivery, type and severity of haemophilia, onset and timing of haemorrhages, site(s) of bleeding, provision of prophylaxis with coagulation factor replacement therapy, and the role played by the federally funded Haemophilia Treatment Centers (HTC) in the management of these infants with haemophilia were evaluated. Seventy-five per cent of haemophilic infants were diagnosed early, in the first month of life, especially those with a family history or whose mothers were known carriers; infants of maternal carriers were more likely to be delivered by C-section. Involvement of an HTC prior to delivery resulted in avoidance of the use of assisted deliveries with vacuum and forceps. Bleeding from the circumcision site was the most common haemorrhagic complication, followed by intra- and extra-cranial haemorrhages and bleeding from heel stick blood sampling. Eight per cent of the infants were administered factor concentrate within 24 h of birth; more than half were treated to prevent bleeding. This study highlights the significant rate and the sites of initial bleeding unique to very young children with haemophilia and underscores the need for research to identify optimal evidence-based recommendations for their management.
Document Type: Research Article
Affiliations: 1: Division of Blood Disorders, Centers for Disease Control and Prevention, Atlanta, GA, USA 2: Wayne State University, Detroit, MI, USA 3: Indiana Haemophilia and Thrombosis Center, Indianapolis, IN, USA 4: Medical College of Wisconsin and Blood Center of Wisconsin, Milwaukee, WI, USA 5: University of Colorado at Denver and Health Sciences Center, Aurora, CO, USA 6: University of California at San Francisco, San Francisco, CA, USA 7: University of New Mexico, Albuquerque, NM, USA 8: Emory University, Atlanta, GA, USA 9: Weill Cornell Medical College, New York, NY, USA 10: Gulf States Haemophilia and Thrombophilia Center, Houston, TX, USA 11: Wyeth Pharmaceuticals, Collegeville, PA, USA 12: Children’s Hospital of Orange County, Orange, CA, USA 13: Retired Division Director, Division of Blood Disorders, Centers for Disease Control and Prevention, Atlanta, GA, USA
Publication date: 01 November 2009